Cargando…

Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma

Identification of new molecular markers has led to the molecular classification of prostate cancer based on driving genetic lesions. The translation of these discoveries for clinical use necessitates the development of simple, reliable and rapid detection systems to screen patients for specific mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhalla, Ritu, Kunju, Lakshmi P, Tomlins, Scott A, Christopherson, Kelly, Cortez, Connie, Carskadon, Shannon, Siddiqui, Javed, Park, Kyung, Mosquera, Juan Miguel, Pestano, Gary, Rubin, Mark A, Chinnaiyan, Arul, Palanisamy, Nallasivam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672354/
https://www.ncbi.nlm.nih.gov/pubmed/23348902
http://dx.doi.org/10.1038/modpathol.2012.234
_version_ 1782272102720602112
author Bhalla, Ritu
Kunju, Lakshmi P
Tomlins, Scott A
Christopherson, Kelly
Cortez, Connie
Carskadon, Shannon
Siddiqui, Javed
Park, Kyung
Mosquera, Juan Miguel
Pestano, Gary
Rubin, Mark A
Chinnaiyan, Arul
Palanisamy, Nallasivam
author_facet Bhalla, Ritu
Kunju, Lakshmi P
Tomlins, Scott A
Christopherson, Kelly
Cortez, Connie
Carskadon, Shannon
Siddiqui, Javed
Park, Kyung
Mosquera, Juan Miguel
Pestano, Gary
Rubin, Mark A
Chinnaiyan, Arul
Palanisamy, Nallasivam
author_sort Bhalla, Ritu
collection PubMed
description Identification of new molecular markers has led to the molecular classification of prostate cancer based on driving genetic lesions. The translation of these discoveries for clinical use necessitates the development of simple, reliable and rapid detection systems to screen patients for specific molecular aberrations. We developed two dual color immunohistochemistry-based assays for the simultaneous assessment of ERG-PTEN and ERG-SPINK1 in prostate cancer. A total of 232 cases from 184 localized and 48 metastatic prostate cancers were evaluated for ERG-PTEN and 284 cases from 228 localized and 56 metastatic prostate cancers were evaluated for ERG-SPINK1. Of the 232 cases evaluated for ERG-PTEN, 81 (35%) ERG positive and 77 (33%) PTEN deleted cases were identified. Of the 81 ERG positive cases, PTEN loss was confirmed in 35 (15%) cases by fluorescence in situ hybridization. PTEN status was concordant in 203 cases (Sensitivity 90%; Specificity 87% (p<0.0001) by both immunohistochemisty and FISH, however, immunohistochemisty could not distinguish between heterozygous and homozygous deletion status of PTEN. Of the 284 cases evaluated for ERG-SPINK1, 111 (39%) cases were positive for ERG. In the remaining 173 ERG negative cases; SPINK1 was positive in 26 (9 %) cases. SPINK1 expression was found to be mutually exclusive with ERG expression; however, we identified two cases, of which, one showed concomitant expression of ERG and SPINK1 in the same tumor foci and in the second case ERG and SPINK1 was seen in two independent foci of the same tumor nodule. Unlike the homogenous ERG staining in cancer tissues, heterogeneous SPINK1 staining was observed in the majority of the cases. Further studies are required to understand the molecular heterogeneity of cases with concomitant ERG-SPINK1 expression. Automated dual ERG-PTEN and ERG-SPINK1 immunohistochemisty assays are simple, reliable and portable across study sites for the simultaneous assessment of these proteins in prostate cancer.
format Online
Article
Text
id pubmed-3672354
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-36723542013-12-01 Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma Bhalla, Ritu Kunju, Lakshmi P Tomlins, Scott A Christopherson, Kelly Cortez, Connie Carskadon, Shannon Siddiqui, Javed Park, Kyung Mosquera, Juan Miguel Pestano, Gary Rubin, Mark A Chinnaiyan, Arul Palanisamy, Nallasivam Mod Pathol Article Identification of new molecular markers has led to the molecular classification of prostate cancer based on driving genetic lesions. The translation of these discoveries for clinical use necessitates the development of simple, reliable and rapid detection systems to screen patients for specific molecular aberrations. We developed two dual color immunohistochemistry-based assays for the simultaneous assessment of ERG-PTEN and ERG-SPINK1 in prostate cancer. A total of 232 cases from 184 localized and 48 metastatic prostate cancers were evaluated for ERG-PTEN and 284 cases from 228 localized and 56 metastatic prostate cancers were evaluated for ERG-SPINK1. Of the 232 cases evaluated for ERG-PTEN, 81 (35%) ERG positive and 77 (33%) PTEN deleted cases were identified. Of the 81 ERG positive cases, PTEN loss was confirmed in 35 (15%) cases by fluorescence in situ hybridization. PTEN status was concordant in 203 cases (Sensitivity 90%; Specificity 87% (p<0.0001) by both immunohistochemisty and FISH, however, immunohistochemisty could not distinguish between heterozygous and homozygous deletion status of PTEN. Of the 284 cases evaluated for ERG-SPINK1, 111 (39%) cases were positive for ERG. In the remaining 173 ERG negative cases; SPINK1 was positive in 26 (9 %) cases. SPINK1 expression was found to be mutually exclusive with ERG expression; however, we identified two cases, of which, one showed concomitant expression of ERG and SPINK1 in the same tumor foci and in the second case ERG and SPINK1 was seen in two independent foci of the same tumor nodule. Unlike the homogenous ERG staining in cancer tissues, heterogeneous SPINK1 staining was observed in the majority of the cases. Further studies are required to understand the molecular heterogeneity of cases with concomitant ERG-SPINK1 expression. Automated dual ERG-PTEN and ERG-SPINK1 immunohistochemisty assays are simple, reliable and portable across study sites for the simultaneous assessment of these proteins in prostate cancer. 2013-01-25 2013-06 /pmc/articles/PMC3672354/ /pubmed/23348902 http://dx.doi.org/10.1038/modpathol.2012.234 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Bhalla, Ritu
Kunju, Lakshmi P
Tomlins, Scott A
Christopherson, Kelly
Cortez, Connie
Carskadon, Shannon
Siddiqui, Javed
Park, Kyung
Mosquera, Juan Miguel
Pestano, Gary
Rubin, Mark A
Chinnaiyan, Arul
Palanisamy, Nallasivam
Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
title Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
title_full Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
title_fullStr Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
title_full_unstemmed Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
title_short Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
title_sort novel dual color immunohistochemical methods for detecting erg-pten and erg-spink1 status in prostate carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672354/
https://www.ncbi.nlm.nih.gov/pubmed/23348902
http://dx.doi.org/10.1038/modpathol.2012.234
work_keys_str_mv AT bhallaritu noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT kunjulakshmip noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT tomlinsscotta noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT christophersonkelly noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT cortezconnie noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT carskadonshannon noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT siddiquijaved noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT parkkyung noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT mosquerajuanmiguel noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT pestanogary noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT rubinmarka noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT chinnaiyanarul noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma
AT palanisamynallasivam noveldualcolorimmunohistochemicalmethodsfordetectingergptenandergspink1statusinprostatecarcinoma